Angiogenesis Serum Protein Quantification for Prostate Pathology

Bălăcescu, Ovidiu; Berindan‐Neagoe, Ioana; Bălăcescu, Loredana; Crişan, Nicolae; Feciche, Bogdan; Tudoran, Oana; Coman, Ioan; Irimie, Alexandru

doi:10.1159/000189664

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This interaction is out of balance in cases of malignancy because of tumor-associated angiogenic factors that can be produced directly by cancer cells or indirectly by inflammatory cells that infiltrate tumor [1–3]. According to existing data, elevated levels of angiogenesis markers in both tumour and serum, have been observed in patients with different types of cancer [8–10]. r, The correlation between levels of angiogenesis regulated factors, clinical pathology and prognosis is very significant, especially in breast cancer [11–13].…”

Section: Introductionmentioning

confidence: 99%

Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

Rykałą

Przybyłowska

Majsterek

et al. 2011

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Tumoural angiogenesis is essential for the growth and spread of breast cancer cells. Therefore the aim of this study was to assess the diagnostic performance of angiogenesis markers in tumours and there reflecting levels in serum of breast cancer patients. Angiogenin, Ang2, fibroblast growth factor basic, intercellular adhesion molecule (ICAM)-1, keratinocyte growth factor (KGF), platelet-derived growth factor-BB, and VEGF-A were measured using a FASTQuant angiogenic growth factor multiplex protein assay. We observed that breast cancer tumours exhibited high levels of PDGF-BB, bFGF and VEGF, and extremely high levels of TIMP-1 and Ang-2, whereas in serum we found significantly higher levels of Ang-2, PDGF-BB, bFGF, ICAM-1 and VEGF in patients with breast cancer compared to the benign breast diseases patients. Moreover, some of these angiogenesis markers evaluated in tumour and serum of breast cancer patients exhibited association with standard clinical parameters, ER status as well as MVD of tumours. Angiogenesis markers play important roles in tumour growth, invasion and metastasis. Our results suggest that analysis of angiogenesis markers in tumour and serum of breast cancer patients using multiplex protein assay can improve diagnosis and prognosis in this diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

Rykałą

Przybyłowska

Majsterek

et al. 2011

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Recent study has found that the level of angiogenesis protein was increased in serum and tumor cells in patients with cancer [ 30 – 32 ]. Angiogenesis is a prognostic indicator for a variety of tumors [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Expression of Angiogenesis Regulatory Proteins and Epithelial-Mesenchymal Transition Factors in Platelets of the Breast Cancer Patients

Han

Cao

Wang

et al. 2014

The Scientific World Journal

View full text Add to dashboard Cite

Platelets play a role in tumor angiogenesis and growth and are the main transporters of several angiogenesis regulators. Here, we aimed to determine the levels of angiogenesis regulators and epithelial-mesenchymal transition factors sequestered by circulating platelets in breast cancer patients and age-matched healthy controls. Platelet pellets (PP) and platelet-poor plasma (PPP) were collected by routine protocols. Vascular endothelial growth factor (VEGF), platelet-derived growth factor BB (PDGF-BB), thrombospondin-1 (TSP-1), platelet factor 4 (PF4), and transforming growth factor-β1 (TGF-β1) were measured by enzyme-linked immunosorbent assay. Angiogenesis-associated expression of VEGF (2.1 pg/106 platelets versus 0.9 pg/106 platelets, P < 0.001), PF4 (21.2 ng/106 platelets versus 10.2 ng/106 platelets, P < 0.001), PDGF-BB (42.9 pg/106 platelets versus 19.1 pg/106 platelets, P < 0.001), and TGF-β1 (15.3 ng/106 platelets versus 4.3 ng/106 platelets, P < 0.001) differed in the PP samples of cancer and control subjects. In addition, protein concentrations were associated with clinical characteristics (P < 0.05). Circulating platelets in breast cancer sequester higher levels of PF4, VEGF, PDGF-BB, and TGF-β1, suggesting a possible target for early diagnosis. VEGF, PDGF, and TGF-β1 concentrations in platelets may be associated with prognosis.

show abstract

“…Elevated levels of serum angiogenic factors have been observed in patients with various cancer types. [6][7][8][9] In addition, the correlation between the serum concentrations of these factors, clinical diagnosis, progonosis, and response to anti-cancer agents is significant. [9][10][11][12][13] Similarly, elevated concentrations of angionenic markers have also been reported in the serum of patients diagnosed with cardiovascular diseases, diabetes mellitus, and liver fibrosis.…”

Section: Introductionmentioning

confidence: 99%

Sensitive, quantitative, and high-throughput detection of angiogenic markers using shape-coded hydrogel microparticles

Al-Ameen

Beer

et al. 2015

Analyst

View full text Add to dashboard Cite

Elevated serum concentrations of angiogenic markers including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) have been correlated with various clinical disorders including cancer, cardiovascular diseases, diabetes mellitus, and liver fibrosis. In addition, the correlation between the serum concentrations of these factors, clinical diagnosis, prognosis, and response to therapeutic agents is significant. Thereby suggesting high-throughput detection of serum levels of angiogenic markers has important implications in early detection of different clinical disorders as well as for subsequent therapy monitoring. Here, we demonstrate the feasibility of utilization of shape-coded hydrogel microparticle based suspension arrays for quantitative and reproducible measurement of VEGF, FGF, and PDGF in single and multiplexed assays. Bio-inert PEG hydrogel attenuated the background signal thereby improving the sensitivity of the detection method as well as eliminating the need for blocking the proteins. In the singleplexed assay, the detection limits of 1.7 pg ml(-1), 1.4 pg ml(-1), and 1.5 pg ml(-1) for VEGF, FGF, and PDGF respectively indicated that the sensitivity of the developed method exceeds that of the conventional technologies. We also demonstrated that in the multiplexed assays, recovery of the proteins was within 20% of the expected values. The practical applicability of the hydrogel microparticle based detection system was established by demonstrating the ability of the system to quantify the production of VEGF, FGF, and PDGF by breast cancer cells (MDA-MB-231).

show abstract

Angiogenesis Serum Protein Quantification for Prostate Pathology

Cited by 5 publications

References 25 publications

Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

Expression of Angiogenesis Regulatory Proteins and Epithelial-Mesenchymal Transition Factors in Platelets of the Breast Cancer Patients

Sensitive, quantitative, and high-throughput detection of angiogenic markers using shape-coded hydrogel microparticles

Contact Info

Product

Resources

About